← All trials
NCT03316300
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 24, 2017
- Primary completion
- Aug 31, 2022
- Completion date
- Aug 31, 2022
- First posted
- Oct 20, 2017
- Last posted
- Mar 17, 2022
- Enrollment
- 115
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Neurotech PharmaceuticalsLead sponsor
- National Eye Institute (NEI)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.